Xiidra (Lifitegrast) Patent Expiration, LOE Window & CMS Spending
Xiidra (Lifitegrast) by Bausch Health: FDA Orange Book core substance LOE 2030-10-21 (last listed 2033-12-18), 0 AB generics, $598.3M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Bausch Health |
| FDA Application & Pathway | N208073 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2030-10-21 |
| Last Listed Patent or Exclusivity Date | 2033-12-18 |
| Orange Book Patents (*PED Extensions) | 11 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $598.3M |
| 2024 Medicare Part D Spend | $505.3M |
| 2024 Medicaid Spend | $93.0M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 23.6% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.
- Predicate Ledger FDA 510(k)Bausch Health / Bausch + Lomb FDA 510(k) & Recall Cohortdevices.meruai.co →
- Protocol Ledger NIH ClinicalTrials.govBausch Health / Bausch + Lomb Clinical Trials & Approvalstrials.meruai.co →
- ERISA Ledger DOL Form 5500Bausch Health / Bausch + Lomb 401(k) & Form 5500 Planerisa.meruai.co →